Navigation Links
TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
Date:6/25/2008

to be studied in clinical trials for chronic pain. Glutamate receptors mediate the functioning of glutamate, an important excitatory neurotransmitter. While normal glutamate production is essential, excess glutamate production, either through injury or disease, can have a range of pathological effects. By acting at both the AMPA and kainate receptor site to competitively block the binding of glutamate, tezampanel and its oral prodrug, NGX426, have the potential to treat a number of diseases and disorders. These include migraine and other forms of chronic pain such as neuropathic pain as well as muscle spasticity and rigidity secondary to spinal cord trauma, stroke and multiple sclerosis.

Webinar Information

Participants can access the Webinar by clicking on the link located on the home page of TorreyPines Therapeutics' Web site at http://www.torreypinestherapeutics.com. Individuals interested in asking questions should also participate via telephone by calling 888-823-7457 in the United States or 973-935-8504 outside of the United States and entering conference ID 48658866. Participants are encouraged to log on at least 15 minutes prior to the beginning of the Webinar. A replay of the Webinar will be available on TorreyPines Therapeutics' Web site until July 25.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates, each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity and rigidity, xerostomia and cognitive disorders. The company is currently developing four product candidates: two ionotropic glutamate receptor antagonists and two muscarin
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
2. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
3. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
4. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
5. Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
6. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
7. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
8. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 Research and ... addition of the "Global Gynecological Devices ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... into wide categories based on their operations. ... of different gynecological conditions that affect the ...
(Date:9/19/2014)... , Sept. 19, 2014  The board of ... declared a quarterly cash dividend of $0.42 per share.  ... 17, 2014 to stockholders of record at the close ... AbbVie AbbVie is a global, research-based biopharmaceutical company formed ... is to use its expertise, dedicated people and unique ...
(Date:9/19/2014)... , Sept. 19, 2014  For Cloud Pharmaceuticals, ... design and development, partnering is an integral part ... to design new drugs and identify early stage, ... to further their development. The company also partners ... support this business model, Cloud Pharmaceuticals will be ...
Breaking Medicine Technology:Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2
... Mass. and SYDNEY, Dec. 2, 2010 HeartWare International, ... leading innovator of less invasive, miniaturized circulatory support technologies ... today announced that CEO Doug Godshall is scheduled to ... & Obesity Conference on Tuesday, December 7, 2010 at ...
... Dec. 2, 2010 Sagent Pharmaceuticals, Inc., a ... approval and launch of its topotecan hydrochloride for ... innovator,s patent expiry.  Sagent,s topotecan is available in ... latest product to feature Sagent,s proprietary PreventIV Measures™ ...
Cached Medicine Technology:HeartWare to Present at the Canaccord Genuity Cardio/Diabetes & Obesity Conference 2Sagent Pharmaceuticals Adds to Its Oncology Portfolio With Launch of Topotecan Hydrochloride for Injection 2
(Date:9/20/2014)... Weight Destroyer , a weight ... Michael Wren that has already helped tens of thousands ... conditions like high blood pressure, high cholesterol, and accelerated ... an investigative review. , “Weight Destroyer is totally ... by showing people what is truly effective when it ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 Villa del ... resort did not experience any damage in relation to ... and activities available. , Hurricane Odile struck Cabo San ... wind, rain and powerful surf conditions. Located on the ... Islands of Loreto experienced some heavy rain, but no ...
(Date:9/20/2014)... On Monday, September 22, Loma Linda ... research grant from Hyundai Hope on Wheels at a ... located on 11234 Anderson St., in Loma Linda. The ... Associate Professor at Loma Linda University and Director of ... children. , Loma Linda University Medical Center ...
(Date:9/20/2014)... The avian flu that killed 160 harbor seals in ... drops and therefore poses a potential threat to humans, ... illnesses have been linked to the harbor seal virus, ... natural mutations to the avian H3N8 seal virus that ... droplets. Current seasonal flu vaccines wouldn,t help in ...
(Date:9/20/2014)... September 20, 2014 New PharmaPoint ... Market Analysis to 2023?. The asthma market saw ... it has become saturated with relatively efficacious standard ... (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and ... generic competition. However, the launch of seven novel ...
Breaking Medicine News(10 mins):Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 2Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 3Health News:Villa del Palmar at the Islands of Loreto Fully Functioning After Hurricane 2Health News:Villa del Palmar at the Islands of Loreto Fully Functioning After Hurricane 3Health News:Loma Linda University Medical Center Receives $250,000 Research Grant From Hyundai Hope On Wheels In Honor Of National Childhood Cancer Awareness Month 2Health News:Loma Linda University Medical Center Receives $250,000 Research Grant From Hyundai Hope On Wheels In Honor Of National Childhood Cancer Awareness Month 3Health News:Avian Flu In Harbor Seals Could Infect People 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 3Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 4
... French . Montreal, July 14, 2010 ... to a new study from the University of Montreal (Canada) ... Molecular Nutrition & Food Research , the investigation analyzed ... notably whether cashew extracts could improve the body,s response to ...
... psychologist at the University of Georgia shows that behavioral economic ... alcohol and other drugs. This method of studying how ... fairly new, but according to the study, it may well ... effective ways to defeat addictions. The research was published ...
... INDIANAPOLIS Pain and depression associated with cancer ... be significantly reduced through centralized telephone-based care management ... from the Regenstrief Institute and Indiana University School ... Depression (INCPAD) study combined automated calls with follow-up ...
... Doheny HealthDay Reporter , TUESDAY, July 13 (HealthDay ... last ",til death do you part" -- or if you ... game may reveal the hidden truth about your union, a ... flawed because it relies on asking the people involved how ...
... protein already used to treat diseases like multiple sclerosis, hepatitis ... patients, UT Southwestern Medical Center researchers have found. ... of a population of immune cells known to cause asthma. ... called T helper 2 cells, or Th2 cells. Under normal ...
... Gardner HealthDay Reporter , TUESDAY, July 13 (HealthDay ... than a decade ago that the blockbuster diabetes drug caused ... information, according to a report published Tuesday in The ... Avandia against its competitor, Actos, the drug company, then known ...
Cached Medicine News:Health News:New analysis may help clarify the role of craving in addiction 2Health News:New analysis may help clarify the role of craving in addiction 3Health News:Help is on the phone: Reducing pain and depression of cancer 2Health News:Word Games May Predict Life of Relationship 2Health News:Word Games May Predict Life of Relationship 3Health News:Interferon might help asthma patients breathe easier, UT Southwestern study suggests 2Health News:Avandia Heart Risks Buried by Drug Company: Report 2Health News:Avandia Heart Risks Buried by Drug Company: Report 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: